Vitiligo is an acquired immune-mediated pigmentary skin disease affecting 1%-2% of worldwide population. 1 First-line therapy for restricted and extensive involvement is topical therapy (corticosteroids [TCS] and calcineurin inhibitors [TCI, tacrolimus, and pimecrolimus]) and narrow-band ultraviolet B (NB-UVB), respectively. 2-5 Nowadays, lasers are used for treatment of difficult-to-treat areas and refractory lesions. Monochromatic excimer laser (MEL)/excimer light (EL) was the first laser used in treatment of vitiligo. Ablative resurfacing